| 于国新,石 峻,韩爱珺,刘明翠,益 华,高积勇.培美曲塞治疗复发性卵巢癌疗效观察及对糖类抗原125、人肿瘤坏死因子α的影响研究[J].,2019,19(24):4785-4788 |
| 培美曲塞治疗复发性卵巢癌疗效观察及对糖类抗原125、人肿瘤坏死因子α的影响研究 |
| Effect of Pemetrexed on Recurrent Ovarian Cancer and Its Effect on Carbohydrate Antigen 125 and Human Tumor Necrosis Factor Alpha |
| 投稿时间：2019-08-24 修订日期：2019-09-18 |
| DOI：10.13241/j.cnki.pmb.2019.24.043 |
| 中文关键词: 卵巢癌 化疗 培美曲塞 肿瘤标志物 |
| 英文关键词: Ovarian cancer Chemotherapy Pemetrexed Tumor markers |
| 基金项目:陕西省卫生计生委科研项目(2016D036) |
|
| 摘要点击次数: 740 |
| 全文下载次数: 379 |
| 中文摘要: |
| 摘要 目的：观察培美曲塞治疗复发性卵巢癌疗效及对糖类抗原125、人肿瘤坏死因子α的影响。方法：回顾性分析2014年3月至2017年6月我院收住院治疗的92例复发性卵巢癌患者的临床资料。根据化疗方式不同分为观察组（培美曲塞）和对照组（紫杉醇联合伊立替康）。统计分析两组患者近期疗效、不良反应、化疗前后血清肿瘤标志物水平。结果：观察组缓解率为60.9%（28/46），明显高于对照组32.6%（15/46），差异具有统计学意义（P<0.05）。观察组骨髓抑制发生率为45.7%（21/46），明显低于对照组67.4%（31/46），差异具有统计学意义（P<0.05）；两组胃肠道反应、脱发、肾功能损害、肝功能损害等不良反应发生率无明显差异（P>0.05）。观察组治疗后CA125、TNF-α水平均明显低于对照组，差异具有统计学意义（P<0.05）。结论：培美曲塞治疗复发性卵巢癌疗效可靠，安全性高，且对降低患者CA125、TNF-α水平具有重要作用，值得临床借鉴使用。 |
| 英文摘要: |
| ABSTRACT Objective: To observe the effect of pemetrexed on recurrent ovarian cancer and its effect on serum CA125, TNF-α level. Methods: From March 2014 to June 2017, 92 cases of recurrent ovarian cancer patients treated in our hospital were chose as study objects. They were divided into two group according to the chemotherapy treatment, the observation group received pemetrexed treatment, the control group received paclitaxel and irinotecan treatment. Statistical analysis of the short-term efficacy, serum tumor markers levels before and after chemotherapy. Results: The remission rate in the observation group was 60.9% (28/46), which was significantly higher than that in the control group (32.6%, 15/46). The difference was statistically significant (P<0.05). The incidence of myelosuppression in the observation group was 45.7% (21/46), which was significantly lower than that in the control group (67.4% (31/46)), and the difference was statistically significant(P<0.05). There was no significant difference between the two groups in the incidence of gastrointestinal reactions, alopecia, renal function damage and liver function damage (P>0.05). The levels of CA125 and TNF-α in the observation group after treatment were significantly lower than those in the control group, and the difference was statistically significant (P<0.05). Conclusion: Pemetrexed is effective and safe for the treatment of recurrent ovarian cancer, and has an important role in reducing the levels of CA125 and TNF-α in patients. It is worthy of clinical reference. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
